Capecitabine (Seven On, Seven Off) with Lapatinib for Metastatic Breast Cancer Refractory to Trastuzumab


Capecitabine (Seven On, Seven Off) with Lapatinib for Metastatic Breast Cancer Refractory to Trastuzumab
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)

Gajria D et al. A novel capecitabine schedule (7 on — 7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab. San Antonio Breast Cancer Symposium 2010;Abstract P6-11-12.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.